Grupos sanguíneos y SARS-COV-2 en personal de salud de un solo centro / Blood groups and SARS-CoV-2 in health professionals from a single center
Keywords:
Infecciones por Coronavirus, Personal de Salud, Sistema del Grupo Sanguíneo ABO / Coronavirus Infections, Health Personnel, ABO Blood-Group SystemAbstract
Resumen
Introducción: la posibilidad de que el grupo sanguíneo (GS) predisponga a infección por SARS-CoV-2 es controversial.
Objetivo: comparar prevalencia de GS, anti-IgG SARS-CoV-2 y síntomas más frecuentes, en personal de salud convaleciente frente a controles previo a la vacunación.
Material y métodos: diseño transversal analítico de casos y controles, que incluyó personal de salud, de marzo a junio de 2020, confirmados con reaccion en cadena de la polimerasa (PCR-SARS-CoV-2) y controles negativos con PCR y anti-IgG-SARS-COV-2. Se les interrogó sobre los síntomas y se determinó el GS. Se empleó estadística descriptiva y análisis comparativo con chi cuadrada o prueba exacta de Fisher y t de Student o U de Mann-Whitney.
Resultados: de 218 trabajadores, 102 (46.8%) fueron casos confirmados para SARS-CoV-2 (convalecientes) y 116 controles. La distribución de GS fue similar entre los casos y los controles y el GS-O+ fue el más frecuente (52.9%). El riesgo de infectarse de SARS-CoV-2 para el GS-O, comparado con GS-No-O mostró menor tendencia: razón de momios [RM] 0.725 (intervalo de confianza del 95% [IC 95%] 0.416-1.261; p = ns). El GS-A (28.4%) comparado con GS-No-A (71.6%) mostró tendencia de incremento del riesgo en GS-A, RM 1.523 (IC 95% 0.818-2.837, p = ns). La presencia de anticuerpos IgG de SARS-CoV-2 fue del 85% en el grupo de convalecientes.
Conclusiones: la prevalencia de infectados fue proporcionalmente mayor para GS-A y menor para GS-O. Alrededor de 15% no desarrollaron anticuerpos de SARS-CoV-2 después de recuperarse de COVID-19.
Abstract
Background: The possibility that the blood group (BG) predisposes to SARS-CoV-2 infection is controversial.
Objective: To compare the prevalence of BG, anti-IgG SARS-CoV-2, and more frequent symptoms in convalescent health personnel vs controls prior to vaccination.
Material and methods: Analytical cross-sectional design of cases and controls, which included health personnel, from March to June 2020, confirmed with (polymerase chain reaction) PCR-SARS-CoV-2 and negative controls with PCR and anti-IgG-SARS-CoV-2. Participants were questioned concerning symptoms and BG was determined. It was used descriptive statistics and comparative analysis with chi squared, Fisher’s exact test, Student’s t, and Mann Whitney’s U tests.
Results: Of 218 workers, 102 (46.8%) were confirmed cases for SARS-CoV-2 (convalescent) and 116 controls. The distribution of BG was similar between cases and controls, being BG-O + the most frequent (52.9%). The risk of becoming infected by SARS-CoV-2 for BG-O compared to BGNo-O showed a lower trend (odds ratio [OR] 0.725, 95% confidence interval [95% CI] 0.416-1.261, p = ns). The BG-A (28.4%) compared with BG-No-A (71.6%) showed a trend of increased risk in BG-A (OR 1.523, 95% CI 0.818-2.837, p = ns). The presence of SARS-CoV-2 IgG antibodies was 85% in the convalescent group. Conclusions: The prevalence of infected was proportionally higher for BG-A and lower for BG-O. About 15% did not develop SARS-CoV-2 antibodies after overcoming COVID-19 disease.
Downloads
References
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33. doi: 10.1056/NEJMoa2001017.
Mojica-Crespo R, Morales-Crespo MM. Pandemia COVID-19, la nueva emergencia sanitaria de preocupación internacional: una revisión. Semergen. 2020; 1:65-77. doi:10.1016/j.semerg.2020.05.010.
Bienvenu LA, Noonan J, Wang X, Peter K. Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities. Cardiovasc Res. 2020;116(14):2197-06. doi:10.1093/cvr/cvaa284.
Ma Y, Hou L, Yang X, Huang Z, Yang X, Zhao N, et al. The association between frailty and severe disease among COVID-19 patients aged over 60 years in China: a prospective cohort study. BMC Med. 2020;18(1):274. doi: 10.1186/s12916-020-01761-0.
Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Health. 2020;13(12):1833-9. doi:10.1016/j.jiph.2020.07.014.
Chen Y, Klein SL, Garibaldi BT, Li H, Wu C, Osevala NM, et al. Aging in COVID-19: Vulnerability, immunity and intervention. Ageing Res Rev. 2021;65:101205. doi:10.1016/j.arr.2020.101205.
Lalueza-Fox C, Gigli E, de la Rasilla M, Fortea J, Rosas A, Bertranpetit J, et al. Genetic characterization of the ABO blood group in Neandertals. BMC Evol Biol. 2008;8:342. doi:10.1186/1471-2148-8-342.
Liu N, Zhang T, Ma L, Zhang H, Wang H, Wei W, et al. The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis. Blood Rev. 2020;100785. doi:10.1016/j.blre.2020.100785.
Muñiz-Diaz E, Llopis J, Parra R, Roig I, Ferrer G, Grifols J, et al. Relationship between the ABO blood group and COVID-19 susceptibility, severity and mortality in two cohorts of patients. Blood Transfus. 2021;19(1):54-63. doi:10.2450/2020.0256-20.
Wu Y, Feng Z, Peng Li P, Yu Q. Relationship between ABO blood group distribution and clinical characteristics in patients with COVID-19. Clin Chim Acta. 2020;509:220-3. doi: 10.1016/j.cca.2020.06.026.
Canizalez-Román A, Campos-Romero A, Castro-Sánchez JA, López-Martínez MA, Andrade-Muñoz FJ, Cruz-Zamudio CK, et al. Blood Groups Distribution and Gene Diversity of the ABO and Rh (D) Loci in the Mexican Population. Biomed Res Int. 2018;2018:1-11. doi: 10.1155/2018/1925619.
Liu X, Wang J, Xu X, Liao G, Chen Y, Hu C. H. Patterns of IgG and IgM antibody response in COVID-19 patients. Emerg Microbes Infect. 2020;9(1):1269-74. doi:10.1080/22221751.2020.1773324.
Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020;71(16):2027-34. doi: 10.1093/cid/ciaa344.
Infantino M, Grossi V, Lari B, Bambi R, Perri A, Manneschi M, et al. Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience. J Med Virol. 2020;92(9):1671-5. doi:10.1002/jmv.25932.
Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020. https://doi.org/10.1038/s41591-020-0913-5.
Procter BC, Ross C, Pickard V, Smith E, Hanson C, McCullough PA. Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. Rev Cardiovasc Med. 2020;21(4):611-4. doi:10.31083/j.rcm.2020.04.260.
McCullough PA, Alexander PE, Armstrong R, Arvinte C, Bain AF, Bartlett RP, et al. Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). Rev Cardiovasc Med. 2020;21(4):517-30. doi:10.31083/j.rcm.2020.04.264.
Golinelli D, Boetto E, Maietti E, Fantini MP. The association between ABO blood group and SARS-CoV-2 infection: A meta-analysis. PLoS One. 2020;15(9):e0239508. doi:10.1371/journal.pone.0239508.
Pendu JL, Breiman A, Rocher J, Dion M, Ruvoën-Clouet N. ABO Blood Types and COVID-19: Spurious, Anecdotal, or Truly Important Relationships? A Reasoned Review of Available Data. Viruses. 2021;13(2):160. doi:10.3390/v13020160.
Batool Z, Durrani SH, Tariq S. Association Of ABO And Rh Blood Group Types To Hepatitis B, Hepatitis C, Hiv And Syphilis Infection, A Five Year' Experience In Healthy Blood Donors In A Tertiary Care Hospital. J Ayub Med Coll Abbottabad. 2017;29(1):90-2.
Franchini M, Liumbruno GM. ABO blood group: old dogma, new perspectives. Clin Chem Lab Med. 2013;51(8):1545-53. doi:10.1515/cclm-2013-0168.
Latz CA, DeCarlo C, Boitano L, Png CYM, Patell R, Conrad MF, et al. Blood type and outcomes in patients with COVID-19. Ann Hematol. 2020;99(9):2113-8. doi:10.1007/s00277-020-04169-1.
Zalba MS, Antelo ML, Galbete A, Etayo M, Ongay E, García-Erce JA. Infection and thrombosis associated with COVID-19: Possible role of the ABO blood group. Med Clin (Barc). 2020;155(8):340-3. doi: 10.1016/j.medcli.2020.06.020.
Li J, Wang X, Chen J, Cai Y, Deng A, Yang M. Association between ABO blood groups and risk of SARS-CoV-2 pneumonia. Br J Haematol. 2020; 190(1):24-7. doi:10.1111/bjh.16797.
Dzik S, Eliason K, Morris EB, Kaufman RM, North CM. COVID-19 and ABO blood. Transfusion. 2020; 60(8): 1883-4. doi.org/10.1111/trf.15946.
Severe Covid-19 GWAS Group. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med. 2020;383(16):1522-34. doi:10.1056/NEJMoa2020283.
Downloads
Published
Issue
Section
License
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.
